Metabolic Interventions To Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Overview

About this study

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement in liver fibrosis, as assessed histologically (via liver biopsy).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Male or female participants between the ages of 18 (or the minimum country-specific age of consent if >18) and 75 years, inclusive, at PreQ and SCR1.
  • Biopsy proven NASH with either F2 or F3 fibrosis, per NASH CRN definition.
  • BMI ≥ 22.5kg/m^2.

Exclusion Criteria:

  • Evidence of other causes of liver disease such as alcoholic steatohepatitis, (de)compensated cirrhosis, active viral hepatitis.
  • Any condition possibly affecting drug absorption.
  • Unstable concomittant medical conditions, based on medical history or screening laboratory results including:
    • unstable liver function tests;
    • recent cardiovascular event(s);
    • significant malignancies;
    • other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Maria Yataco, M.D.

Closed for enrollment

Contact information:

Maria Yataco

9049563200

yataco.maria@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Alina Allen, M.D., M.S.

Closed for enrollment

Contact information:

Jessica Olson

5072939123

olson.jessica3@mayo.edu

More information

Publications

Publications are currently not available